Cortechs.ai Gains FDA Clearance for NeuroQuant PET
COVINGTON, Ky., August 18, 2026 Cortechs.ai announced that its NeuroQuant® PET platform has received FDA 510(k) clearance (K261916) for...
PET imaging
Advertisement
Curium to Merge with Lantheus in $8B Radiopharma Deal
Boston & Bedford, Massachusetts, August 3, 2026 Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement...
Tiziana Life Sciences Reports Positive Foralumab Data in Third MSA Patient
BOSTON, July 31, 2026 Tiziana Life Sciences announced new quantitative PET imaging results from the third patient with Multiple...
RefleXion Submits FDA 510(k) for Anchor Point Tracking
HAYWARD, Calif., June 30, 2026 RefleXion Medical has announced the submission of a 510(k) premarket notification to the U.S....
AC Immune Reports Positive Phase 1 ALS Imaging Data for ACI-19626
LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...
Advertisements
Bayer PET Tracer Shows Promise in Amyloidosis Study
BERLIN, Germany / WHIPPANY, N.J., May 7, 2026 Bayer announced positive topline results from the pivotal Phase III REVEAL...
Telix NDA Accepted for Pixclara Brain Cancer Imaging
Melbourne, Australia & Indianapolis, USA | April 10, 2026 Telix Pharmaceuticals has announced that the U.S. Food and Drug...
Clarity Co-PSMA Shows Superior Prostate Cancer Detection
SYDNEY, Australia, March 31, 2026 Clarity Pharmaceuticals has announced the publication of Phase II Co-PSMA clinical trial results in...
TLX101-Px MAA Filed in Europe for Brain Cancer Imaging
MELBOURNE, AUSTRALIA & INDIANAPOLIS, UNITED STATES — February 18, 2026 Telix Pharmaceuticals has submitted a European Marketing Authorization Application...
Telix Reports Phase 3 Success and FDA Progress in Dx
MELBOURNE, Australia; INDIANAPOLIS, United States — December 22, 2025 — Telix Pharmaceuticals Limited has reported a major precision medicine...
Advertisement
